AlphaMadera's AlphaVal page computes Precigen, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag PGEN as undervalued, fairly valued, or overvalued.

What is Precigen, Inc.'s fair value?

Fair value for PGEN is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value PGEN?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from PGEN's most recent reported fundamentals.

PGEN - Precigen, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $11.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

No positive earnings available for stable earnings model